Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Opinion
Biden Decision on Weight-Loss Drugs a Push-Back on Progressives
Last week, the Biden administration passed a rule allowing for the government healthcare programs Medicare and Medicaid coverage of a class of
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Study participants treated with Zepbound lost 20% of their body weight. A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight loss is most effective at helping people lose more weight in less time.
Eli Lilly’s Zepbound Outperforms Competitor in Weight Loss Trial, Supporting Buy Rating
Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating on December 2.Don't Miss our
Lilly to Boost Weight-Loss Drug Supply With $3 Billion Expansion
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its blockbuster diabetes and weight-loss drugs.
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical trial backed by Lilly.
Eli Lilly's Zepbound takes on Novo Nordisk's Wegovy in obesity drug showdown
In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that its weight loss treatment, Zepbound (tirzepatide), outperformed Novo Nordisk’s Wegovy (semaglutide) in a recent clinical trial.
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Wegovy and Zepbound are leading this year's weight loss drug prescription surge
The weight loss revolution is in full swing, with the number of patients receiving Wegovy (NVO) having doubled while those receiving Zepbound have tripled since January 2024.
4d
Weight-loss drugs deliver life-changing health benefits - and big profits
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
Endocrinology Advisor
4d
Self-Stigma Linked to Greater Dropout, Engagement in Weight Loss Program
Self-stigma was associated with higher dropout rates, engagement, and weight loss among individuals who completed a weight loss program.
The Associated Press on MSN
10d
Cheap Ozempic? How millions of Americans with obesity may get access to costly weight-loss drugs
Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...
2d
Postpartum Weight Loss: 3 Steps to Get Started (& More Tips & Tricks)
Postpartum weight loss can feel impossible at times, especially if the weight isn’t coming off as quickly as you expected.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback